Issues and unmet needs in advanced prostate cancer

Author(s): Koen Slabbaert and Hein Van Poppel

The development of new therapeutic agents in advanced prostate cancer has developed in past years. Several new drugs have been created and find their place inbetween the classic luteinizing hormone-releasing hormone-agonists, antiandrogens and chemotherapeutic agents. The demand for new drugs was especially high because of the poor prognosis for patients with castration-resistant prostate cancer. Degarelix, abiraterone, TAK-700 (orteronel), cabazitaxel, Sipuleucel-T and MDV3100 are examples of new drugs that give hope of better survival for prostate cancer patients.